HOUSTON--(BUSINESS WIRE)--DNAtrix Inc., a biotech company focusing on the development of oncolytic viruses for cancer, announced today that the lead clinical program from the company, DNX-2401, has been selected as one of the “Top Advanced Therapies Projects to Watch” by Elsevier. As the result of this recognition, Dr. Frank Tufaro, chief executive officer of DNAtrix, will be presenting at Elsevier Business Intelligence’s Therapeutic Area Partnerships Conference taking place in Boston on November 19, 2013 at 2:55 pm Eastern time.
Help employers find you! Check out all the jobs and post your resume.
